Drugs / B013
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06434610 | Jul 2024 → Dec 2026 expected | — | Shanghai Jiaolian Drug Research and Development Co., Ltd | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05555706 | Dec 2022 → Sep 2024 | triple-negative breast carcinoma | Shanghai Jiaolian Drug Research and Development Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05555706 ↗ |
| Route | Intravenous | “via intravenous (IV) infusion” NCT05555706 ↗ |